Aenova and Haupt Pharma To Merge - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aenova and Haupt Pharma To Merge



The Aenova Group, a provider of development and manufacturing services for medicines and dietary supplements reported it will merge with Haupt Pharma, a company specializing in contract development and manufacturing. An agreement has been signed, but the purchase price remains confidential. The transaction will proceed subject to the approval of the relevant competition authorities, but is expected to become legally binding at the end of 2013.

The merger will add areas such as sterile manufacturing and the production of special active ingredients (including hormones, antibiotics, and cytostatics) to Aenova.

Aenova’s network will increase from eight to 21 sites including production facilities in Germany (Berlin, Brackenheim, Münster, Gronau, Regensburg, Wolfratshausen) and in Europe, its first site in Japan. The number of employees will increase from 2,500 to more than 4,000.

Source: Aenova Group

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here